Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Bristol Myers Squibb (BMY) and Pfizer announced that Eliquis (apixaban) will be sold on Mark Cuban Cost Plus Drug Company starting April 27, 2026, offering a 30-day supply for a total cash price of $345. The move expands direct-to-patient access for cash-paying customers alongside the existing Eliquis 360 Support option.
The announcement reiterates Eliquis indications for AFib, DVT/PE, and post-orthopedic surgery, and includes Important Safety Information about bleeding risks and use limitations.
Pfizer (NYSE: PFE) declared a $0.43 per-share quarterly cash dividend for second-quarter 2026, payable June 12, 2026 to holders of record at the close of business on May 8, 2026.
This will be Pfizer's 350th consecutive quarterly dividend.
Pfizer (NYSE: PFE) will present new oncology data at ASCO 2026 (May 29–June 2) covering over 40 abstracts, including three late-breaking sessions and eight oral presentations.
Key highlights include a 7‑year CROWN update supporting lorlatinib as first-line ALK+ NSCLC, BREAKWATER PFS/OS data for a BRAFTOVI regimen in BRAF V600E mCRC, TALAPRO-3 topline rPFS benefit for TALZENNA + XTANDI in mCSPC, and HER2CLIMB-05 maintenance results for TUKYSA. Multiple next-generation programs (PF‑08634404, sigvotatug vedotin, atirmociclib) advance toward Phase 3 testing.
Astellas and Pfizer (NYSE: PFE) announced the FDA has accepted for Priority Review a supplemental BLA for perioperative PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) to treat muscle-invasive bladder cancer (MIBC) regardless of cisplatin eligibility. EV-304 Phase 3 data showed a 47% reduction in risk of recurrence/progression and a 35% reduction in risk of death; pCR was 55.8% vs 32.5% for chemotherapy. The PDUFA target action date is August 17, 2026.
Pfizer (NYSE: PFE) invites shareholders and the public to its virtual 2026 Annual Meeting on April 23, 2026 at 9:00 a.m. EDT. Shareholders may log in beginning at 8:45 a.m. EDT using a control number to vote or ask questions; listen-only access requires no control number.
Advance question deadline is April 21, 2026 at 5:00 p.m. EDT. Replay will be posted within 24 hours and available for up to one year.
Pfizer (NYSE: PFE) will host a webcast and conference call with analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026 to discuss its First Quarter 2026 Performance Report. Registration and webcast access are available at www.pfizer.com/investors.
The live call can also be heard by phone (U.S./Canada: 800-456-4352; international: 785-424-1086) using passcode 74607. A transcript and replay will be posted within 24 hours and remain available for at least 90 days.
Pfizer (NYSE: PFE) and Valneva reported Phase 3 VALOR results for investigational Lyme vaccine PF-07307405 (LB6V), showing ~73–75% efficacy versus placebo in pre-specified analyses. The candidate was well tolerated with no safety concerns identified at analysis. Fewer-than-expected cases limited statistical power; Pfizer plans regulatory submissions.
Key metrics: efficacy 73.2% (28 days post-dose 4) and 74.8% (1 day post-dose 4), with wide 95% CIs. Collaboration grants Pfizer exclusive manufacturing and commercialization rights upon approval.
Pfizer (NYSE: PFE) warns shareholders to reject an unsolicited mini-tender offer by Tutanota LLC to buy up to 1,000,000 shares at $32.00 per share.
The offer equals ~0.02% of outstanding shares (as of March 9, 2026), is conditioned on the closing price exceeding $32.00, may be extended to April 13, 2026, and is subject to financing and other conditions that may not be satisfied.
Pfizer (NYSE: PFE) reported positive topline Phase 3 TALAPRO-3 results: TALZENNA plus XTANDI met the primary endpoint with a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus placebo plus XTANDI, exceeding the pre-specified hazard ratio target of 0.63.
Consistent benefit was seen in BRCA and non-BRCA HRR gene–mutated metastatic castration-sensitive prostate cancer; an interim analysis showed a strong trend toward improved overall survival. Results will be presented and discussed with global health authorities.
Pfizer (NYSE: PFE) reported positive topline Phase 2 FOURLIGHT-1 results for atirmociclib in HR+, HER2- metastatic breast cancer, meeting the primary endpoint with a 40% reduction in risk of progression or death (HR 0.60; 95% CI 0.440–0.825; p=0.0007).
Results were consistent across prespecified subgroups, >90% of patients started atirmociclib within three months of prior CDK4/6 inhibitor therapy, overall survival was immature (~20% events), and safety was manageable with 6.4% discontinuations due to adverse events. Phase 3 first-line study is ongoing.